PREDICTIVE VALUE OF MGMT PROMOTER METHYLATION QUANTITATIVE ASSESSMENT IN GLIOBLASTOMA, WHICH OPTIMAL CUT-POINT?

被引：0
|
作者：
de Saint-Denis, T. [1 ]
Lerhun, E. [1 ]
Ramirez, C. [1 ]
Devos, P. [2 ]
Maurage, C. A. [3 ]
Dubois, F. [1 ]
Reyns, N. [1 ]
Escande, F. [4 ]
机构：
[1] CHRU Lille, F-59037 Lille, France
[2] CHRU Lille, Dept Biostat, F-59037 Lille, France
[3] CHRU Lille, Serv Anat Pathol, F-59037 Lille, France
[4] CHRU Lille, Ctr Biol & Patol, F-59037 Lille, France
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P04.10
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma
    Gonzalez Jimenez, Victor
    Brell Doval, Marta
    Gomez Bellvert, Cristina
    Goliney Goliney, Victor
    Salazar Asencio, Osman
    Gomez Martin, Adriana
    Ibanez Dominguez, Javier
    [J]. NEUROPATHOLOGY, 2023, 43 (04) : 306 - 312
  • [22] The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
    Zhang, Kui
    Wang, Xiao-qin
    Zhou, Bin
    Zhang, Lin
    [J]. FAMILIAL CANCER, 2013, 12 (03) : 449 - 458
  • [23] The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
    Kui Zhang
    Xiao-qin Wang
    Bin Zhou
    Lin Zhang
    [J]. Familial Cancer, 2013, 12 : 449 - 458
  • [24] Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach
    Unal, Ilker
    [J]. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2017, 2017
  • [25] Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma
    Kristensen, Lasse S.
    Michaelsen, Signe R.
    Dyrbye, Henrik
    Aslan, Derya
    Grunnet, Kirsten
    Christensen, Ib J.
    Poulsen, Hans S.
    Gronbaek, Kirsten
    Broholm, Helle
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2016, 75 (03): : 246 - 255
  • [26] The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide
    Rapkins, Robert W.
    Wang, Fan
    Nguyen, HuyTram N.
    Cloughesy, Timothy F.
    Lai, Albert
    Ha, Wendy
    Nowak, Anna K.
    Hitchins, Megan P.
    McDonald, Kerrie L.
    [J]. NEURO-ONCOLOGY, 2015, 17 (12) : 1589 - 1598
  • [27] Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity
    Rocca, Andrea
    Brigliadori, Giovanni
    Calistri, Daniele
    Foca, Flavia
    Dall'Agata, Monia
    Rengucci, Claudia
    Cerasoli, Serenella
    Faedi, Marina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials
    Binabaj, Maryam Moradi
    Bahrami, Afsane
    ShahidSales, Soodabeh
    Joodi, Marjan
    Mashhad, Mona Joudi
    Hassanian, Seyed Mahdi
    Anvari, Kazem
    Avan, Amir
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (01) : 378 - 386
  • [29] MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
    Rivera, Andreana L.
    Pelloski, Christopher E.
    Gilbert, Mark R.
    Colman, Howard
    De La Cruz, Clarissa
    Sulman, Erik P.
    Bekele, B. Nebiyou
    Aldape, Kenneth D.
    [J]. NEURO-ONCOLOGY, 2010, 12 (02) : 116 - 121
  • [30] THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PARTIAL MGMT PROMOTER METHYLATION FOR IDH-WILDTYPE GLIOBLASTOMA PATIENTS
    Torre, Matthew
    Iorgulescu, Bryan
    [J]. NEURO-ONCOLOGY, 2022, 24 : 10 - 10
12345